A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus

BACKGROUND: Direct-acting antivirals are successful in curing hepatitis C virus infection in more than 95% of patients treated for 12 weeks, but they are expensive. Shortened treatment durations, which may have lower cure rates, have been proposed to reduce costs. OBJECTIVES: To evaluate the lifetim...

Descripción completa

Detalles Bibliográficos
Autores principales: Fawsitt, Christopher G., Vickerman, Peter, Cooke, Graham, Welton, Nicky J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588649/
https://www.ncbi.nlm.nih.gov/pubmed/31198187
http://dx.doi.org/10.1016/j.jval.2018.12.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588649/
https://www.ncbi.nlm.nih.gov/pubmed/31198187
http://dx.doi.org/10.1016/j.jval.2018.12.011

Ejemplares similares